Azur Pharma Ltd.

45 Fitzwilliam Square
Dublin 2
Ireland.

tel:
+353 1 634 4183
fax:
+353 1 634 4170

Azur Pharma Inc.

1818 Market Street
Suite 2350
Philadelphia
PA 19103
USA.

tel:
+1 215 832 3750
fax:
+1 215 832 3789

Welcome

Azur Pharma is a private pharmaceutical company focused on therapeutic areas of CNS and Women's Health markets of the US. The company is headquartered in Dublin, Ireland.

Azur Pharma markets a portfolio of prescription products through its US national sales infrastructure consisting of three specialty sales forces, two in CNS and the other a Women's Health force. Azur Pharma's portfolio comprises of CNS products including FazaClo® and Prialt®, Women's Health and Urology products including Elestrin®, and an orphan disease product, Gastrocrom®. FazaClo® is an antipsychotic drug indicated for the management of severely ill schizophrenic patients who fail to respond to standard treatments. FazaClo® also is indicated for reduction in the risk of recurrent suicidal behaviour in schizophrenia or schizoaffective disorders. Prialt® is indicated for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatments. Elestrin® is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Gastrocrom® is indicated for the management of patients with mastocytosis.

Azur Pharma's mission is to build an integrated pharmaceutical company focused on the areas of CNS and women’s health. Azur Pharma's strategy is to acquire marketed products and late stage development opportunities in our target markets to leverage the specialist sales forces we have developed for these markets.

The company was founded in May 2005 with a private equity funding of €40 million ($60 million). Since that time, Azur Pharma has acquired Gastrocrom®, Niravam® and Parcopa® from UCB Pharma, Pharmelle a Women's Health and Urology business, FazaClo® from Avanir Pharmaceuticals, Elestrin® from BioSante, and Prialt® from Elan. Azur Pharma also completed an additional €35 million ($50 million) equity financing in August 2007.

We invite you to explore our web site and learn more about Azur Pharma.